Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
0.9000
0.00 (0.00%)
Jul 30, 2026, 1:01 PM EST

BCLI Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-8.91-9.95-11.69-21.44-24.82-24.54
Net Income
-9.57-10.31-11.62-17.19-24.28-24.46
Earnings Per Share
-0.92-1.11-2.31-5.99-9.97-10.20
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.020.030.191.32.9822.09
Total Debt
1.491.181.021.284.095.08
Net Cash (Debt)
-1.47-1.15-0.830.03-1.1117.02
Net Cash Growth
------50.99%
Net Cash Per Share
-0.14-0.12-0.170.01-0.467.05

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-6.66-6.98-9.09-20.46-19.32-26.27
Capital Expenditures
----0.02-0.03-0.33
Free Cash Flow
-6.66-6.98-9.09-20.48-19.35-26.6
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.